BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Information letter on Kineret® (anakinra) 100 mg and 100 mg/0.67 ml solution for injection in a pre-filled syringe: Visible solid deposits on the surface of the needle

2015.06.16

Active substance: anakinra

The Swedish company Orphan Biovitrum AB (Sobi) issues information on deposits of the active substance on the surface of the needle.

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 155KB, File is accessible